DE3788385T2 - Pyrimidin-Derivate. - Google Patents
Pyrimidin-Derivate.Info
- Publication number
- DE3788385T2 DE3788385T2 DE87306868T DE3788385T DE3788385T2 DE 3788385 T2 DE3788385 T2 DE 3788385T2 DE 87306868 T DE87306868 T DE 87306868T DE 3788385 T DE3788385 T DE 3788385T DE 3788385 T2 DE3788385 T2 DE 3788385T2
- Authority
- DE
- Germany
- Prior art keywords
- pyrimidine
- pyrazolyl
- imidazolyl
- methoxy
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000003230 pyrimidines Chemical class 0.000 title claims description 15
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title description 4
- -1 xyloxy group Chemical group 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 18
- 125000001425 triazolyl group Chemical group 0.000 claims description 17
- 125000002883 imidazolyl group Chemical group 0.000 claims description 15
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 15
- ITORZLJASZQARK-UHFFFAOYSA-N 4,6-di(pyrazol-1-yl)pyrimidine Chemical compound C1=CC=NN1C1=CC(N2N=CC=C2)=NC=N1 ITORZLJASZQARK-UHFFFAOYSA-N 0.000 claims description 11
- HDRFFLHBLUPAKE-UHFFFAOYSA-N 4-chloro-6-pyrazol-1-ylpyrimidine Chemical compound C1=NC(Cl)=CC(N2N=CC=C2)=N1 HDRFFLHBLUPAKE-UHFFFAOYSA-N 0.000 claims description 10
- 125000004104 aryloxy group Chemical group 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 8
- 239000000460 chlorine Substances 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- DCQGLKJULMYXAV-UHFFFAOYSA-N 4-chloro-2-imidazol-1-ylpyrimidine Chemical compound ClC1=CC=NC(N2C=NC=C2)=N1 DCQGLKJULMYXAV-UHFFFAOYSA-N 0.000 claims description 6
- BOBHIPMYQAROLL-UHFFFAOYSA-N 4-chloro-6-imidazol-1-ylpyrimidine Chemical compound C1=NC(Cl)=CC(N2C=NC=C2)=N1 BOBHIPMYQAROLL-UHFFFAOYSA-N 0.000 claims description 6
- JZJJPJWXORKLGK-UHFFFAOYSA-N 4-imidazol-1-yl-6-methoxypyrimidine Chemical compound C1=NC(OC)=CC(N2C=NC=C2)=N1 JZJJPJWXORKLGK-UHFFFAOYSA-N 0.000 claims description 6
- DWNKNOSIDWJEBZ-UHFFFAOYSA-N 2,4-di(imidazol-1-yl)pyrimidine Chemical compound C1=NC=CN1C1=CC=NC(N2C=NC=C2)=N1 DWNKNOSIDWJEBZ-UHFFFAOYSA-N 0.000 claims description 5
- MGIZVNWCIFAMCT-UHFFFAOYSA-N 2,4-di(pyrazol-1-yl)pyrimidine Chemical compound C1=CC=NN1C1=CC=NC(N2N=CC=C2)=N1 MGIZVNWCIFAMCT-UHFFFAOYSA-N 0.000 claims description 5
- AJNAMVHKXSFJFJ-UHFFFAOYSA-N 2-chloro-4-imidazol-1-ylpyrimidine Chemical compound ClC1=NC=CC(N2C=NC=C2)=N1 AJNAMVHKXSFJFJ-UHFFFAOYSA-N 0.000 claims description 5
- MLTSBTVXGJSIOQ-UHFFFAOYSA-N 2-imidazol-1-yl-4-methoxypyrimidine Chemical compound COC1=CC=NC(N2C=NC=C2)=N1 MLTSBTVXGJSIOQ-UHFFFAOYSA-N 0.000 claims description 5
- HYNIJNUNVBFXNN-UHFFFAOYSA-N 2-methoxy-4-methyl-6-(1,2,4-triazol-1-yl)pyrimidine Chemical compound COC1=NC(C)=CC(N2N=CN=C2)=N1 HYNIJNUNVBFXNN-UHFFFAOYSA-N 0.000 claims description 5
- AZHKZTUILYWBHY-UHFFFAOYSA-N 4,6-di(imidazol-1-yl)pyrimidine Chemical compound C1=NC=CN1C1=CC(N2C=NC=C2)=NC=N1 AZHKZTUILYWBHY-UHFFFAOYSA-N 0.000 claims description 5
- GYWARUMEOXBMQX-UHFFFAOYSA-N 4-ethoxy-2-imidazol-1-yl-6-methylpyrimidine Chemical compound CCOC1=CC(C)=NC(N2C=NC=C2)=N1 GYWARUMEOXBMQX-UHFFFAOYSA-N 0.000 claims description 5
- ZSXAXULNRYCRRQ-UHFFFAOYSA-N 4-ethoxy-6-methyl-2-pyrazol-1-ylpyrimidine Chemical compound CCOC1=CC(C)=NC(N2N=CC=C2)=N1 ZSXAXULNRYCRRQ-UHFFFAOYSA-N 0.000 claims description 5
- JMOIYFQXFXBKRH-UHFFFAOYSA-N 4-methoxy-6-methyl-2-pyrazol-1-ylpyrimidine Chemical compound COC1=CC(C)=NC(N2N=CC=C2)=N1 JMOIYFQXFXBKRH-UHFFFAOYSA-N 0.000 claims description 5
- RECQJRLJPPRICN-UHFFFAOYSA-N 4-methoxy-6-pyrazol-1-ylpyrimidine Chemical compound C1=NC(OC)=CC(N2N=CC=C2)=N1 RECQJRLJPPRICN-UHFFFAOYSA-N 0.000 claims description 5
- OYMRGNAOABAKMM-UHFFFAOYSA-N 4-phenoxy-6-pyrazol-1-ylpyrimidine Chemical compound C=1C(N2N=CC=C2)=NC=NC=1OC1=CC=CC=C1 OYMRGNAOABAKMM-UHFFFAOYSA-N 0.000 claims description 5
- BUCREIZRYQPPRS-UHFFFAOYSA-N 4-piperidin-1-yl-6-pyrazol-1-ylpyrimidine Chemical compound C1CCCCN1C1=CC(N2N=CC=C2)=NC=N1 BUCREIZRYQPPRS-UHFFFAOYSA-N 0.000 claims description 5
- XYYWPIPDUIKOSX-UHFFFAOYSA-N 4-propan-2-yloxy-6-pyrazol-1-ylpyrimidine Chemical compound C1=NC(OC(C)C)=CC(N2N=CC=C2)=N1 XYYWPIPDUIKOSX-UHFFFAOYSA-N 0.000 claims description 5
- WAQXCJDLNSZZSS-UHFFFAOYSA-N 6-pyrazol-1-ylpyrimidin-4-amine Chemical compound C1=NC(N)=CC(N2N=CC=C2)=N1 WAQXCJDLNSZZSS-UHFFFAOYSA-N 0.000 claims description 5
- 208000025865 Ulcer Diseases 0.000 claims description 5
- 125000003386 piperidinyl group Chemical group 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 231100000397 ulcer Toxicity 0.000 claims description 5
- AONCLSDFPYXELL-UHFFFAOYSA-N 2-imidazol-1-yl-4-methoxy-6-methylpyrimidine Chemical compound COC1=CC(C)=NC(N2C=NC=C2)=N1 AONCLSDFPYXELL-UHFFFAOYSA-N 0.000 claims description 4
- HLVKQBZLEAKKJG-UHFFFAOYSA-N 4-methoxy-6-methyl-2-(1,2,4-triazol-1-yl)pyrimidine Chemical compound COC1=CC(C)=NC(N2N=CN=C2)=N1 HLVKQBZLEAKKJG-UHFFFAOYSA-N 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 3
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 2
- 230000000767 anti-ulcer Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 description 50
- 150000001875 compounds Chemical class 0.000 description 43
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 42
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 37
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 36
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 36
- 238000000034 method Methods 0.000 description 29
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 239000000203 mixture Substances 0.000 description 24
- 238000002844 melting Methods 0.000 description 18
- 230000008018 melting Effects 0.000 description 18
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 239000011541 reaction mixture Substances 0.000 description 14
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- 238000001953 recrystallisation Methods 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- 125000001246 bromo group Chemical group Br* 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- XJPZKYIHCLDXST-UHFFFAOYSA-N 4,6-dichloropyrimidine Chemical compound ClC1=CC(Cl)=NC=N1 XJPZKYIHCLDXST-UHFFFAOYSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 150000003852 triazoles Chemical class 0.000 description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- BTTNYQZNBZNDOR-UHFFFAOYSA-N 2,4-dichloropyrimidine Chemical compound ClC1=CC=NC(Cl)=N1 BTTNYQZNBZNDOR-UHFFFAOYSA-N 0.000 description 3
- HBGCZKKCKKDPOI-UHFFFAOYSA-N 2-chloro-4-methoxy-6-methylpyrimidine Chemical compound COC1=CC(C)=NC(Cl)=N1 HBGCZKKCKKDPOI-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 description 3
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
- VEGXTHMAVSWQTH-UHFFFAOYSA-N 2-chloro-4-ethoxy-6-methylpyrimidine Chemical compound CCOC1=CC(C)=NC(Cl)=N1 VEGXTHMAVSWQTH-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 208000008469 Peptic Ulcer Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 208000011906 peptic ulcer disease Diseases 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- RWBSNBWWYMFNMM-UHFFFAOYSA-N 2-pyrazol-1-yl-1h-pyrimidin-6-one Chemical class OC1=CC=NC(N2N=CC=C2)=N1 RWBSNBWWYMFNMM-UHFFFAOYSA-N 0.000 description 1
- GDMBLTYGBYSZOC-UHFFFAOYSA-N 2-pyrazol-1-ylpyrimidine Chemical class C1=CC=NN1C1=NC=CC=N1 GDMBLTYGBYSZOC-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ONOSIHCSUIEICE-UHFFFAOYSA-N 4-chloro-2-methoxy-6-methylpyrimidine Chemical compound COC1=NC(C)=CC(Cl)=N1 ONOSIHCSUIEICE-UHFFFAOYSA-N 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010042220 Stress ulcer Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001298 n-hexoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61184484A JPS6339875A (ja) | 1986-08-05 | 1986-08-05 | ピリミジン誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3788385D1 DE3788385D1 (de) | 1994-01-20 |
| DE3788385T2 true DE3788385T2 (de) | 1994-05-11 |
Family
ID=16153982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE87306868T Expired - Fee Related DE3788385T2 (de) | 1986-08-05 | 1987-08-03 | Pyrimidin-Derivate. |
Country Status (5)
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0421266A1 (de) * | 1989-10-06 | 1991-04-10 | BASF Aktiengesellschaft | Azolylpyrimidin- und -triazinderivate und sie enthaltende Mittel |
| JPH0710859B2 (ja) * | 1990-05-10 | 1995-02-08 | 日清食品株式会社 | ビスアゾリルピリミジン誘導体の製造方法 |
| DE4131924A1 (de) * | 1991-09-25 | 1993-07-08 | Hoechst Ag | Substituierte 4-alkoxypyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel |
| US5318975A (en) * | 1993-02-16 | 1994-06-07 | Berlex Laboratories, Inc. | 5-pyrimdineamine derivatives |
| US6432947B1 (en) | 1997-02-19 | 2002-08-13 | Berlex Laboratories, Inc. | N-heterocyclic derivatives as NOS inhibitors |
| AU732969B2 (en) * | 1997-02-19 | 2001-05-03 | Berlex Laboratories, Inc. | (N)-heterocyclic derivatives as NOS inhibitors |
| US7037916B2 (en) | 1999-07-15 | 2006-05-02 | Pharmacopeia Drug Discovery, Inc. | Pyrimidine derivatives as IL-8 receptor antagonists |
| US6525051B2 (en) | 2000-03-27 | 2003-02-25 | Schering Aktiengesellschaft | N-heterocyclic derivatives as NOS inhibitors |
| JP4186484B2 (ja) * | 2002-03-12 | 2008-11-26 | 住友化学株式会社 | ピリミジン化合物およびその用途 |
| US6982259B2 (en) | 2002-04-30 | 2006-01-03 | Schering Aktiengesellschaft | N-heterocyclic derivatives as NOS inhibitors |
| US20050014753A1 (en) * | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
| CN100424083C (zh) * | 2006-10-14 | 2008-10-08 | 广西民族大学 | 一种嘧啶衍生化合物及其制备方法 |
| EP2417123A2 (en) | 2009-04-06 | 2012-02-15 | Agios Pharmaceuticals, Inc. | Therapeutic compositions and related methods of use |
| WO2010119878A1 (en) * | 2009-04-16 | 2010-10-21 | Sumitomo Chemical Company, Limited | Pyrimidine compound and its use for pest control |
| WO2010119879A1 (en) * | 2009-04-16 | 2010-10-21 | Sumitomo Chemical Company, Limited | Pyrimidine compound and its use for pest control |
| DK2448581T3 (en) | 2009-06-29 | 2017-03-13 | Agios Pharmaceuticals Inc | Therapeutic compositions and methods for their applications |
| CN102481300B (zh) | 2009-06-29 | 2015-04-15 | 安吉奥斯医药品有限公司 | 治疗性化合物和组合物 |
| MX2013006900A (es) | 2010-12-17 | 2013-10-17 | Agios Pharmaceuticals Inc | Nuevos derivados n-(4-(azetidina-1-carbonil)fenil)-(hetero-)arilsu lfonamida como moduladores piruvato quinasa m2 (pmk2). |
| WO2012088314A1 (en) | 2010-12-21 | 2012-06-28 | Agios Pharmaceuticals, Inc. | Bicyclic pkm2 activators |
| TWI549947B (zh) | 2010-12-29 | 2016-09-21 | 阿吉歐斯製藥公司 | 治療化合物及組成物 |
| PL3406251T3 (pl) | 2011-05-03 | 2024-04-29 | Agios Pharmaceuticals, Inc. | Aktywatory kinazy pirogronianowej do stosowania w terapii |
| US9181231B2 (en) | 2011-05-03 | 2015-11-10 | Agios Pharmaceuticals, Inc | Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia |
| US9200001B2 (en) * | 2011-10-06 | 2015-12-01 | Merck Sharp & Dohme Corp. | Triazolyl PDE10 inhibitors |
| WO2014139144A1 (en) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| EP3285581B1 (en) * | 2015-03-26 | 2021-08-11 | Merck Sharp & Dohme Corp. | Pyrazolyl pyrimidinone compounds as pde2 inhibitors |
| PT3307271T (pt) | 2015-06-11 | 2023-10-10 | Agios Pharmaceuticals Inc | Métodos de utilização de ativadores da piruvato-cinase |
| SG10202111808WA (en) | 2015-08-11 | 2021-11-29 | Novartis Ag | 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer |
| US12024492B2 (en) * | 2019-04-18 | 2024-07-02 | Upl Ltd | Process for preparation of azoxystrobin and intermediates thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3040047A (en) * | 1960-04-04 | 1962-06-19 | Takeda Pharmaceutical | 2-(pyrazol-1-yl)-pyrimidine derivatives |
| US3647814A (en) * | 1969-07-03 | 1972-03-07 | Rohm & Haas | Method for preparing 4-substituted-1 2 4-triazoles |
| US3914223A (en) * | 1972-10-16 | 1975-10-21 | Rohm & Haas | 1,2,4,-4H-Triazole derivatives |
| JPS54115384A (en) * | 1978-02-28 | 1979-09-07 | Hokko Chem Ind Co Ltd | Ryrazolyl pyrimidine derivative, and agricultural and horticultural fungicides |
| US4725600A (en) * | 1984-07-13 | 1988-02-16 | Fujisawa Pharmaceutical Co., Ltd. | Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent |
| JP2761673B2 (ja) * | 1990-12-14 | 1998-06-04 | 株式会社テイエルブイ | 熱応動式スチ―ムトラップ |
-
1986
- 1986-08-05 JP JP61184484A patent/JPS6339875A/ja active Granted
-
1987
- 1987-08-03 EP EP87306868A patent/EP0257850B1/en not_active Expired - Lifetime
- 1987-08-03 DE DE87306868T patent/DE3788385T2/de not_active Expired - Fee Related
- 1987-08-05 CA CA000543812A patent/CA1291757C/en not_active Expired - Fee Related
- 1987-08-05 US US07/082,056 patent/US4849424A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE3788385D1 (de) | 1994-01-20 |
| JPS6339875A (ja) | 1988-02-20 |
| EP0257850B1 (en) | 1993-12-08 |
| US4849424A (en) | 1989-07-18 |
| CA1291757C (en) | 1991-11-05 |
| EP0257850A3 (en) | 1989-08-23 |
| JPH0524917B2 (US07816562-20101019-C00012.png) | 1993-04-09 |
| EP0257850A2 (en) | 1988-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3788385T2 (de) | Pyrimidin-Derivate. | |
| EP0005205B1 (de) | Substituierte 5,6-Dimethylpyrrolo(2,3-d)pyrimidine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel | |
| DE69014351T2 (de) | Pyridincarbonsäureamid-Derivate und diese enthaltende pharmazeutische Zusammensetzungen. | |
| DE69110254T2 (de) | Hydroxychinolonderivate. | |
| DE2952279A1 (de) | Neue 2-acylaminomethyl-1,4-benzodiazepine und deren salze sowie verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel | |
| DE2625227A1 (de) | Heteroarylverbindung, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische mittel | |
| DE3874358T2 (de) | 4-(3h)-chinazolinon-derivate, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen. | |
| EP1529041B1 (de) | Neue prodrugs von 1-methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carbonsäure-(n -2-pyridil-n-2-hydroxycarbonylethyl)-amid, ihre herstellung und ihre verwendung als arzneimittel | |
| DE2838892A1 (de) | 2-substituierte-5-hydroxy-1h-imidazol-4-carboxamid-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische mittel | |
| DE69404158T2 (de) | 4-alkylamino-1-phenoxyalkyl piperidine als antiinflammatorische, antiallergische und immunomodulierende wirkstoffe | |
| WO1996002539A1 (de) | Substituierte triazolylmethylphenylnaphthyridone | |
| EP0180115A2 (de) | 1,2,4-Triazolo-carbamate und ihre Säureadditionssalze, Verfahren zu ihrer Herstellung und Arzneimittel | |
| EP0298921B1 (de) | 1,2-Benzisoxazole und 1,2-Benzisothiazole | |
| EP0411735A1 (de) | Cycloakylenazole, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese enthalten sowie ihre Verwendung zur Herstellung von Arzneimitteln | |
| DE69424215T2 (de) | Verfahren zur Herstellung von 1-(1,2,4-Triazol-1-yl)-propan-2-ol-Derivaten | |
| DE10064997A1 (de) | Benzoylpyridazine | |
| DE2308883A1 (de) | Neue substituierte 2-phenylamino-imidazoline-(2), deren saeureadditionssalze, diese enthaltende arzneimittel und verfahren zur herstellung derselben | |
| EP0004529B1 (de) | Tantomere Arylaminoimidazolinderivate, deren Herstellung und sie enthaltende Arzneimittel zur Bekämpfung von Schmerzzuständen | |
| DE2242454A1 (de) | 1-aethyl-imidazole, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel | |
| DE68913167T2 (de) | Indol-Derivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate. | |
| EP0518457A1 (de) | Bicyclisch substituierte Vinylimidazole, -triazole und -tetrazole | |
| EP0041242A1 (de) | Carbamoyloxyamino-1,4-benzodiazepine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel | |
| DE69707080T2 (de) | Pyrrolidinonderivate und ihre Verwendung als antipsychotische Arzneimittel | |
| DE69113773T2 (de) | Verwendung von 3-aryl-5-alkylthio-4H-1,2,4-triazolen zur Behandlung von Überreflexen infolge von Rückenmarkstrauma. | |
| EP0037471B1 (de) | 1-Aroyl-2-phenylamino-2-imidazoline, ihre Herstellung und diese enthaltende Arzneimittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |